GSK plc (GLAXF)
PNK · Drug Manufacturers - General
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Peers in Healthcare
GSK plc has no peer companies in this window.
Recent press releases
April 2026
GSK Buys Back 965,671 Shares in Latest Buyback Program
# 🧾 What This Document Is This is a **Form 6-K** from GSK plc, a required monthly filing for foreign companies listed in the U.S. Its sole purpose is to announce one specific action: the company bought back some of its own shares on April 22, 2026. Think of it as a receipt and official notice for a
GSK plc files technical memo analyzing internal transaction data structure
The data provided consists of sequential records, each representing a transaction or an event. Assuming this structure is representative of transactional data, it's best used for analysis, data loading, or reporting. Here is a structured overview of the data's presumed components: ### Data Structu
GLAXF Files 6-K With Technical Activity Log Data
Here is a summary of the provided data, categorized by the key elements present: **Data Source:** Log/Activity log **Timeframe:** Multiple timestamps throughout the recording. **Key Entities:** * **Coordinates/Values:** Numeric measurements. * **Tags/Context:** Descriptive labels. ### Analysis by
GSK (GLAXF) submits 6-K detailing routine system activity logs
The provided data is a log of time-stamped events, likely representing network or system activity. To make it more usable, I have organized it into a structured table format. Here is the structured data: | Timestamp | Event Details | | :--- | :--- | | 2024-04-29 13:00:00 | 2024-04-29 13:00:00 | |
GSK's Blenrep is China's first anti-BCMA drug for multiple myeloma
# 📰 What This Document Is 📰 This document is a Form 6-K, which is a report filed by a foreign private issuer (GSK plc) with the U.S. Securities and Exchange Commission. Think of it as an international progress report that lets U.S. investors know about important operational updates happening outs
GSK Buys Back 330,000 Shares on April 9
# 🧾 What This Document Is This is a **Form 6-K** from GSK plc, a standard monthly filing that foreign companies use to update the SEC. This specific filing announces a routine share buyback. Think of it as a public receipt for a stock shopping spree the company completed on a single day. # 🏢 What
GSK Buys Back 335,000 Shares on April 2
# 🧾 What This Document Is This is a **Form 6-K**, a routine report that foreign companies like GSK file with the U.S. Securities and Exchange Commission (SEC) to announce material events. This specific report announces that GSK bought back some of its own shares on the open market. Think of it as a
GSK plc — 6-K Filing
# 🧾 What This Document Is This is a Form 6-K, a report GSK files with the U.S. SEC as a foreign company. It's a formal announcement confirming the completion of a major ownership change within its key HIV business. Essentially, it’s the official "it's done" notice to investors. # 🏢 ViiV Healthcar
March 2026
GSK plc — 6-K Filing
# 🧾 What This Document Is This is a **Form 6-K**, a monthly report GSK files with the U.S. SEC as a foreign company. Think of it as a "news bulletin" update for investors. This specific filing contains one major announcement: the **regulatory approval of a new drug in China**. 👉 **Why it matters:
GSK plc — 6-K Filing
# 🧾 What This Document Is This is a **Form 6-K** from GSK, a monthly update required for foreign companies listed on U.S. stock exchanges. It's a **news release** announcing a major regulatory milestone for one of its key drugs. 👉 In simple terms: GSK is telling the world, "Our promising new hepa
SEC filings
All filings →Insider trades
All insider trades →GSK plc has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at GSK plc
All people →No officers or directors have been indexed for GSK plc.